Open AccessP539: PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX‐351 OR FLUDARABINE‐BASED INDUCTION.
Author(s) -
Guolo F.,
Minetto P.,
Riva C.,
Parodi F.,
Miglino M.,
Tedone E.,
Colombo N.,
Carminati E.,
Nurra C.,
Cagnetta A.,
Cea M.,
Lemoli R. M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845044.63530.d2
Subject(s) - medicine , fludarabine , minimal residual disease , cytarabine , oncology , gemtuzumab ozogamicin , context (archaeology) , idarubicin , regimen , myeloid leukemia , leukemia , chemotherapy , cyclophosphamide , stem cell , cd33 , biology , paleontology , genetics , cd34
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom